BIOTECH PHARMA SUMMIT'17

29-31 March 2017 | Porto, Portugal

Biosimilars & Biologics: The Future of Biotech Medicines

BENEFITS OF ATTENDING

- Hear latest regulatory updates for smooth and speedy approval
- Learn successful biosimilar case studies to reshape your business model
- Dissect regional market growth opportunities – where should you go next ?
- Network with like-minded senior experts and engage in interactive debates

KEY PRACTICAL LEARNING POINTS OF THE SUMMIT:

- The latest trends of the Biosimilars & Biologics
- Successful Commercialization of Biosimilars in the USA/Canada/Europe/India
- Innovative products and technologies in the global biologics market
- Challenges and opportunities in development of Biosimilars & Biologics
- Industry Partnerships: Key Success Factor to win in Biosimilar Space
- Regulatory Advice on Designing Biosimilar Trials
- Strategies for accelerating Biosimilars development and approval
- Biosimilars in emerging markets – regulatory and commercial considerations
- Strategies and competing products for a successful commercialization

Featured Speakers

Edward Abrahams, USA
President
at Personalized Medicine Coalition

Narendra Chimule, IN
Senior VP, Head of R&D
at Biocon

Klaus Lindpaintner, USA
VP and Global Head, Human Genetics
and Computational Biomedicine
at Pfizer Inc

Barbara Valenta-Singer, AT
VP Clinical Development
Operations
at Shire

Cecil Nick, UK
VP (Technical)
at PAREXEL Consulting

Joanna Brougher, USA
Biotech, Pharma and Medical
Device IP and Corporate Counsel;
Adjunct Lecturer,
at Harvard School of Public Health

EPM Group

Program Chair

David Brindley, UK
Chief Scientific Officer, Aegate;
Managing Partner, IP Asset
Ventures; Senior Research Fellow,
at University of Oxford

Program Commitee

António Pregueiro, CH
VP Life Sciences Europe
at HighPoint Solutions

Barbara Valenta-Singer, AT
VP Clinical Development
Operations
at Shire

Cecil Nick, UK
VP (Technical)
at PAREXEL Consulting

Edward Abrahams, USA
President
at Personalized Medicine Coalition

Joanna Brougher, USA
Biotech, Pharma and Medical
Device IP and Corporate Counsel;
Adjunct Lecturer,
at Harvard School of Public Health

Michael Muenzberg, CH
VP, Director Medical Affairs
Biosimilars at Merck Serono

Samir Kulkarni, IN
Associate Vice President, R&D
at Intas Biopharmaceuticals

Steinar Madsen, NO
Medical director
at Norwegian Medicines Agency

Arnout Ploos van Amstel, CH
Head of Global Business
Franchise Immunology &
Dermatology (I&D)
at Novartis Pharmaceuticals

Beatrix Metzner, DE
Director Global CMC Strategy
and Tech RA
at Boehringer Ingelheim

Dairine Dempsey, UK
VP, Strategic Regulatory
Affairs at ICON plc

Fiona M. Greer, UK
Global Director - Life Sciences,
at SGS

Klaus Lindpaintner, USA
VP and Global Head, Human Genetics
and Computational Biomedicine
at Pfizer Inc

Narendra Chirmule, IN
Senior VP, Head of R&D
at Biocon

Shane Maloney, SE
Transaction Director
at AstraZeneca

EXPERTS FROM AROUND THE WORLD IN ONE PLACE

EPM Group is proud to present The BioTech Pharma Summit 2017, taking place in 29-31 of March 2017 in Porto, Portugal.

Over 200 delegates working in biosimilars and biologics, proteins, antibodies and peptides, representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will be joining the Global summit in Porto, reserve your seat now!The BioTech Pharma Summit 2017 will address issues around biosimilars science, global regulatory pathways, evidence for clinical applications, and education for prescribers and patients that are key to successful uptake of these products.

JOIN US FOR A SERIES OF KEYNOTES, PRESENTATIONS AND ROUNDTABLES

Learn best practices on the global R&D and regulatory landscape, designing biosimilar development programmes and bioanalytics of biosimilars.

> "The quality of attendees – as well as speakers – was the key differentiator for me."
>
> David Brindley, DPhil MEng FRSA | Senior Research Fellow Healthcare Translation

Who should attend

The BioTech Pharma Summit 2017 is an exclusive event designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed members of academic and government institutions.
Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

- Biologics/Biotechnology/ Biogenerics
- Biopharmaceuticals
- Business Development
- Chief Scientific Officer
- Clinical Immunology
- Commercial Affairs
- Drug and Safety Assessment
- Drug Safety & Risk Management
- Health Economics
- Intellectual property
- Legal Affairs
- Legislation and Policy Advice
- Manufacturing
- Market Strategy
- Marketing & sales
- New Product Development
- Pharmacovigilance
- Preclinical and Clinical Development
- Pricing and Reimbursement
- Principal Scientist
- Process Control and Analytical
- Technologies
- Quality Affairs/ Quality Control
- Regulatory Affairs
- Regulatory Compliance
- R & D

From Industries Including

- Pharmaceutical and biotechnology

About us

EPM Group is a unique company that promotes global summits, conferences, B2B (business-to-business) meetings, seminars, workshops and develops collaborations between all enterprises in order to promote business development in all areas.

New trends, Innovations, Modern technologies, New products, Emerging topics are generated for senior level executives to provide a cutting edge of business information and maximum return of investment for our clients from different areas, such as Pharmaceutical, Renewable Energy, Oil & Gas, Logistics and Supply Chain and Infrastructure.

Our goal is to become a top event company of designing, producing and delivering highly conceptual and fully integrated events.

Day 0 - Networking

08:20 **Douro River Cruise (all-inclusive)**

There is no better way of getting to know the Douro River than by taking a trip by ship. In this day you will have the opportunity to meet the speakers, do networking before the event and relax with the wonderful views of Porto.

21:00 **Pre-Summit Dinner**

Meet with other attendees before the Summit starts and dine at a 5* Porto panoramic restaurant, offering spectacular views across Porto. Porto's dining scene revolves mainly around fresh sea produce and succulent local meats, with regional delicacies such as francesinhas and bacalhau, the local salted cod, taking center stage, you do not want to miss this dinner.

Day 1 - Conference

08:30 **Registration and Welcome Coffee**

9:30 **Opening of the BioTech Pharma Summit**

Evolution, latest Trends and Future of Biosimilars & Biologics

9:40 **Case Study | Michael Muenzberg** - VP, Director Medical Affairs Biosimilars **at Merck Serono**

The current and future state of the Biosimilars Industry

- Progresses that will have impact in the research and development in the Biosimilars
- Current Approvals and Pipeline agents

10:10 **Case Study | António Pregueiro** - Vice President Life Sciences Europe **at HighPoint Solutions**

Biosimilars: A market to grow

- Biosimilars: current state and future challenges
- Leading companies and key drivers
- Market Opportunities and Forecast

10:40 **Morning Coffee and Networking Break**

11:10 **Case Study | David Brindley** - Chief Scientific Officer, Aegate; Managing Partner, IP Asset Ventures; Senior Research Fellow, **at University of Oxford**

Challenges and opportunities in development of Biosimilars: Global Perspective

- Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market
- New guidance from FDA to help manufacturers develop more treatment options

Regulatory Landscape & Patent Protection

11:40 **Case Study | Joanna Brougher** - Biotech, Pharma and Medical Device IP and Corporate Counsel; Adjunct Lecturer **at Harvard School of Public Health**

Obtaining patent protection while operating in an "anti-patent" climate

- Overview of recent cases affecting the biotechnology industry
- Impact on biosimilar development
- Strategies for obtaining adequate patent protection

12:10 **Q&A with the speakers of the morning sessions**

13:00 **Business Lunch**

14:30 **Case Study | Dairine Dempsey** - VP, Strategic Regulatory Affairs **at ICON plc**
Overview of the regulatory Landscape for Biologics and Biosimilars

- A summary of the global regulations for biologics and biosimilars
- Similarities and differences between the key geographies
- Challenges and opportunities in biologics and biosimilar licencing

15:00 **Case Study | Beatrix Metzner** - Director Global CMC Strategy and Tech RA **at Boehringer Ingelheim**
Regulatory approaches

- Regulatory pathways – general approach
- Building a scientific bridge
- Recent approvals and pipelines analysis
- Successful Biosimilar approval process

15:30 **Coffee Break**

Investments, Business Models and Developing Partnerships

16:00 **Case Study | Shane Maloney** - Transaction Director **at AstraZeneca**
Developing partnerships and making deals

- Environment for deal making
- Getting to a deal
- Leveraging partnerships for success

16:30 **Case Study | Barbara Valenta-Singer** - VP Clinical Development Operations **at Shire**
Industry partnerships: Key success Factors in Biosimilar Space

- Stand-alone situation: high R&D costs, unclear regulatory pathways, uncertain business model, incomplete portfolios
- We will win together through innovative partnership models
- Translation to the biosimilar space

17:00 **Case Study | Arnout Ploos van Amstel** - Head of Global Business Franchise Immunology & Dermatology (I&D) at Novartis
Sustainable biotech innovation and the emergence of biosimilars: opportunities to create enterprise synergies and enhance patient outcomes

- Biotech produced transformational breakthroughs for patients
- Need to balance reward for innovation with increasing budget impact
- Emergence of biosimilars creates opportunities to address this challenge
- Biotech innovation and biosimilars under one roof: enterprise strategies

17:30 **Q&A with the speakers of the afternoon sessions**

18:00 **Chairman's Closing Remarks**

19:30 **Gala Dinner**
We have programmed a dinner in one of the finest restaurants of the city of Porto

Day 2 - Conference

08:30 **Registration & Coffee**

9:30 **Opening Address from the Chairman**

Methods & Analytical Strategies for Biologics and Biosimilars

9:40 **Case Study | Klaus Lindpaintner** - VP and Global Head, Human Genetics and Computational Biomedicine **at Pfizer Inc**
Human Genetic and Computational Biomedicine Approaches in Drug Discovery and Development

10:10 ▶ **Case Study | Fiona M Greer** - Global Director, BioPharma Services Development – Life Sciences **at SGS**
Establishing "Finger-print Like" Biosimilarity – Critical Characterization Strategies for Biosimilar Assessment

- Comprehensive physicochemical structural characterization of the (glyco)protein to demonstrate "Biosimilarity" with the originator
- Glycosylation and variability of quality attributes to establish the QTTP
- Comparative data for the Biosimilar side by side with the originator. Structural and functional activities
- Strategies for primary and higher-order structure determination. LC/MS/MS approaches. Orthogonal analytical techniques for "finger-print like" assessment

10:40 ▶ **Coffee & Networking Break**

11:10 ▶ **Case Study | Cecil Nick** - VP (Technical) **at PAREXEL Consulting**
Analytical Comparability of Biologics and Biosimilars

- Applying state of the art techniques
- Value and limitations of analytical and biological testing
- Assigning criticality to quality attributes
- Statistical approaches
- Justifying differences in critical quality attributes

Clinical trial design and development of biosimilars

11:40 ▶ **Case Study | Narendra Chimule** - Senior VP Head of R&D **at Biocon**
Biosimilarity assessment: Assessing variability, and tiering approaches the process of designing biosimilars

- The process of designing biosimilars
- Quality by design elements
- Critical quality attributes
- Process attributes
- Statistical approaches for DOE

12:10 ▶ **Q&A with the speakers of the morning sessions**

13:00 ▶ **Business Lunch**

14:30 ▶ **Case Study | Steinar Madsen** - Medical director **at Norwegian Medicines Agency**
Biosimilars in emerging markets – regulatory and commercial considerations

- Attitudes and acceptance in clinical practice
- Uptake in clinical practice
- Nor-Switch study and other clinical trials
- Switching and interchangeability

Manufacturing & Commercialization of Biosimilars

15:00 ▶ **Case Study | Edward Abrahams** - President **at Personalized Medicine Coalition**
Biosimilarity assessment: Assessing variability, and tiering approaches the process of designing biosimilars

- FDA Approvals: Getting to USA Market
- Speed your Biosimilars commercialization in the market.
- What are potential partners business models strategies and competing products for a successful commercialization

15:30 ▶ **Coffee Break**

16:00 ▶ **Case Study | Samir Kulkarni** - Associate VP, Product Development and Strategic Program Management at Intas Biopharmaceuticals
Process development in R&D for event free manufacturing

- Investigating the role of R&D before transfer of process ownership
- Establishing critical aspects which requires evaluation to ensure event free manufacturing operations
- Communication and training to prepare for successful technology transfer and manufacturing processes (Associated Real-Life Examples)

16:30 ▶ **Q&A with the speakers of the afternoon sessions**

17:00 ▶ **Panel discussion**

- Global debate on naming of biosimilars
- What can we expect as we moving closer to 2020?
- Partnerships play in the development of biosimilars

Panelists:
Steinar Madsen | Medical director at Norwegian Medicines Agency
Edward Abrahams | President at Personalized Medicine Coalition
Cecil Nick | VP (Technical) at PAREXEL Consulting

17:30 ▶ **Chairman's Closing Remarks and End of Summit**

Speakers Biographies

1

António Pregueiro, CH

VP Life Sciences Europe
at HighPoint Solutions

António Pregueiro, PhD has over 12 years of experience in the pharmaceutical and biotechnology industries combined with a strong research background prior to his business career. Following his graduate training, he spent 5 years working in consulting firms focused in the life-sciences developing expertise in strategy, management and technology across several therapeutic areas. He worked globally, gaining experience in the US, Europe, South America, Russia and the Middle East. He then spent 8 years working in biotech and pharmaceutical companies across functions in analytics, marketing and operations, at companies like Amgen, Bausch & Lomb and Takeda. In his most recent industry position at Takeda he was the head of a business unit for a EU5 country with full P&L responsibility and leading a sales and marketing organization responsible for launching the company´s flagship biologic product.

Barbara Valenta-Singer, AT

VP Clinical Development Operations
at Shire

Barbara Valenta-Singer is a highly motivated, self-driven senior executive, feeling comfortable with change and living transformational leadership. Curious to assess new ways of driving success by engaging cross functional teams with the spirit to allow people to bring their skillset to the table. Having operated in affiliates, regional and global environment in multiple roles like Medical, Clinical, Regulatory, Pharmacovigilance and Compliance she is used to see different perspectives and focus on the big picture. Success and motivation is the result of a team and not of a single individual - leading by example, being authentic and doing the right things is a critical value which has significantly influenced her decision making and leadership style. Developing People, challenging them to operate outsite their comfort zone and identifying their potential is a key strength of her. Barbara has decided to move on to new challenges where she can support growing teams with her 'big picture' view, passion to get things done and motivate by Leadership.

Beatrix Metzner, DE

Director Global CMC Strategy
and Tech RA
at Boehringer Ingelheim

Dr. Beatrix Metzner studied chemistry at the University of Regensburg and Freiburg, Germany where she specialized in biochemistry. Furthermore she was a PhD student at the Department of Experimental Dermatology at the University of Freiburg, Germany and Post Doctoral research Fellow at the Memorial Sloan-Kettering Cancer Center in New York, USA. From 2000 she worked at MediGene AG, Germany as Senior Scientist and later as Senior CMC Project Manager. In 2005 she started at Merck KGaA, Germany as CMC Project Manager. In 2007 she moved to Global Regulatory Oncology where she has been working as Director Global Regulatory Oncology until November 2013 responsible for global regulatory strategy of biological products. Beatrix started working for Boehringer-Ingelheim, Germany as Director CMC Strategy and Tech RA responsible for CMC regulatory strategy of new biological entities (NBEs) and biosimilars at Boehringer Ingelheim. Since July 2016 she acts the Head of Global Tech RA.

Cecil Nick, UK

VP (Technical)
at PAREXEL Consulting

Cecil Nick, Vice President (Technical), at PAREXEL Consulting has been working in regulatory affairs and clinical development for over 30 years; for over 25 years he has focused on biological medicines. Cecil Nick has particular expertise in monoclonals and biosimilars, having worked on over 20 such programs, engaged in over 50 interactions and meetings with regulatory agencies in the EU, US, Canada, Australia, Mexico, Brazil and supported 6 submissions in the EU and US including the first monoclonal biosimilar to be approved in the EU and US.. He has participated extensively in Industry and International meetings on the subject. Additionally, Cecil Nick has extensive experience in orphan drugs and in numerous therapeutic areas including, but not limited to, oncology, inflammatory disease, diabetes, growth and hematology.

Dairine Dempsey, UK

VP, Strategic Regulatory
Affairs at ICON plc

Dr. Dempsey is Vice President, Strategic Regulatory Affairs at ICON plc, a global clinical research organisation (CRO). She is a PhD pharmacist with over 15 years' experience as a pharmaceutical regulator. She has previously held a number of senior positions in the Irish competent authority (HPRA) where she represented Ireland at the European Medicines Agency, the European Commission and internationally. She later worked as a pharmaceutical consultant to pharmaceutical companies & governments in the EU, US & globally during which time she led the establishment of Bahrain's national regulatory agency for pharmaceutical products regulation. She is currently responsible for global regulatory strategy at ICON plc.

David Brindley, UK

Chief Scientific Officer, Aegate;
Managing Partner, IP Asset Ventures; Senior Research Fellow, at University of Oxford

Dr David Brindley is an international research and industrial leader in healthcare translation. He holds academic appointments at the University of Oxford, Harvard, UCL, Stanford-UCSF-FDA Centre for Regulatory Sciences and CASMI, and is an enthusiastic and diligent advisor to a portfolio of healthcare sector companies, ranging from tools and technologies providers to life science focussed investors.
David is a Managing Partner at IP Asset Ventures Ltd. He is also Chief Scientific Officer of Aegate Ltd., who are world leaders in medicines authentication, ensuring compliance with the EU Falsified Medicines Directive (FMD) and US Drug Supply Chain Security Act (DSCSA).

Edward Abrahams, USA

President
at Personalized Medicine Coalition

Edward Abrahams, Ph.D., is the president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.
Previously, Dr. Abrahams was the executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania's investment of $200 million to commercialize biotechnology in the state. Earlier, he had been assistant vice president for federal relations at the University of Pennsylvania and held a senior administrative position at Brown University.

Fiona M. Greer, UK

Global Director - Life Sciences,
at SGS

Dr Fiona Greer was a founding Director of M-Scan (Mass Spectrometry Consultants and Analysts), contract analytical laboratories specializing in biopharmaceutical characterization. Following acquisition in 2010, she is now Global Director, Biopharma Services Development, SGS Life Sciences.
Following a Ph.D. in Protein Biochemistry from Aberdeen University (1984) she joined M-Scan to establish and direct biologics characterization services. Here, she pioneered and applied new developments in Mass Spectrometry for structural analysis and sequencing of proteins and carbohydrates resulting in numerous publications and patents. She was instrumental in expansion of the group, establishing a US facility where she was appointed VP.

Joanna Brougher, USA

Biotech, Pharma and Medical Device IP and Corporate Counsel;
Adjunct Lecturer,
at Harvard School of Public Health

Joanna is a patent attorney who focuses her practice on all aspects of services related to patents in the life sciences. Joanna has experience counseling clients on the Hatch-Waxman Act and is monitoring developments involving biosimilars under the Biologics Price Competition and Innovation Act. Joanna is also an Adjunct Lecturer at the Harvard T.H. Chan School of Public Health and the Editor-in-Chief of the Journal of Commercial Biotechnology. She regularly speaks or lectures on intellectual property related topics and is a frequent author of articles related to patent law and healthcare. In 2013, Joanna published a book called Intellectual Property and Health Technologies: Balancing Innovation and the Public's Health which examines the relationship between patents and public health in the context of medical technologies. Joanna received her J.D. degree from Boston College Law School, and is admitted to the Massachusetts and New York State Bars as well as the USPTO.

Klaus Lindpaintner, USA

VP and Global Head, Human Genetics and Computational Biomedicine
at Pfizer Inc

Dr. Klaus N. Lindpaintner, MD, MPH., serves as Chief Scientific Officer, Analytical Technologies at Thermo Fisher Scientific. Dr. Lindpaintner served as the Chief Scientific Officer and Vice President of Research & Development at Strategic Diagnostics Inc. from February 1, 2010 to September 25, 2012. Dr. Lindpaintner served as Vice President of Research of F. Hoffmann at La Roche Ltd. and served as its Director of the "Roche Molecular Medicine Laboratories" and Global Head, Molecular Medicines Policy and External Affairs. He has served on numerous working groups and advisory panels for trade organizations, regulatory authorities and non-governmental institutions on issues related to scientific aspects as well as ethical and societal impacts of novel technologies in biomedicine.

Michael Muenzberg, CH

VP, Director Medical Affairs
Biosimilars
at Merck Serono

Dr. Mike Muenzberg is VP Global Medical Director at the Merck Serono Biosimilar Unit. He was born in Austria and educated in Austria, Canada and Sweden. Dr. Muenzberg is licensed as Doctor of Nuclear Medicine and has more than 15 years' experience in Pharmaceutical Industry, working as local as well as global Medical Manager/Director for Serono, Novartis, Amgen, Roche and Sandoz International Biopharmaceuticals. Since 2014 Dr. Muenzberg holds his position as VP Global Medical Director Biosimilars at the Merck Serono Biosimilar Unit, responsible for pipeline Biosimilars.

Narendra Chimule, IN

Senior VP, Head of R&D
at Biocon

Biocon

Dr. Narendra Chirmule is the head of Research & Development at Biocon Limited since 2015 and Senior Vice President since February 25, 2016. With over 23 years of experience in Immunology, Mr. Chirmule has held senior leadership positions at Amgen and Merck, in the US, in the departments of Clinical Immunology overseeing drug development in regulated laboratories. He is an expert in the area of immune responses to biologics and vaccines.
He has teaching and research experience as Assistant Director at the Human Gene Therapy Group of University of Pennsylvania. He is an advisor to the Filovirus consortium and a reviewer on the HIV vaccine study section for the National Institutes of Health. He is also an academician conducting Biotech educational seminars and has published extensively (more than 100) on the topics of immunogenicity prediction and assessment, predictive toxicology and quality-by-design. Mr. Chirmule completed his post-doctoral training at Cornell University Medical College, New York. Mr. Chirmule is a MS (Zoology, Animal Physiology) and Ph.D. In Applied Biology from the University of Mumbai.

Samir Kulkarni, IN

Associate Vice President, R&D
at Intas Biopharmaceuticals

INTAS

Dr. Samir Kulkarni is leading the Process Development efforts at Intas Biopharmaceuticals as an Associate Vice President. He holds a PhD in Chemical Engineering in addition to which, his educational background includes a combination of faculties such as Pharmaceutical Sciences, BioProcessing and Business Administration from Reputed institutes such as ICT (Mumbai) and IIM (Bangalore).
Samir has more than 16 years of experience in the area of biological sciences with strong technical depth in Protein Chemistry and Process development having worked in the Biopharma Development Groups at Dr. Reddy's Laboratories and USV in his earlier tenures. His experience extends into overall understanding of Biologics and Pharma Product Development business through managing Biosimilars Programs at Dr Reddy's Biologics and as the global Business Development lead for Accutest Biologics. He holds about 11 Patent applications in Process Development of Biologics to his credit along with several research papers published in peer reviewed journals.

Shane Maloney, SE

Transaction Director
at AstraZeneca

AstraZeneca

Shane Maloney is a Transaction Director in AstraZeneca's business development group, based in Gothenburg, Sweden. He has worked in business development for AstraZeneca since 2001, originally in the UK and now in Sweden; and starting with technology platforms and early-discovery deals, before gradually moving to clinical-stage and on-market deals. Prior to joining AstraZeneca, Shane worked in university technology transfer, out-licensing inventions as well as managing spin-out companies. By training, he is a PhD microbiologist with an MBA.

Steinar Madsen, NO

Medical director
at Norwegian Medicines Agency

Statens legemiddelverk
Norwegian Medicines Agency

Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost-effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.

Arnout Ploos van Amstel, CH

Head of Global Business
Franchise Immunology &
Dermatology (I&D)
at Novartis

NOVARTIS

Arnout Ploos van Amstel has over 25 years of business and operations experience in the bio-pharmaceutical business in a wide variety of leadership positions. Currently, Mr Ploos van Amstel leads the Global Business Franchise Immunology & Dermatology (I&D) at Novartis Pharmaceuticals. The I&D Business of $3,2bn includes the recently launched, game changing biologic Cosentyx, the first IL17A inhibitor. Cosentyx addresses significant unmet needs for patients with the skin disease Psoriasis and the rheumatology disorders Psoriatric Arthritis (PsA) and Ankylosing Spondylitis (AS). It is one of the most promising assets of Novartis.
Apart from dermatology and rheumatology, the I&D portfolio includes orphan diseases and the transplant- and liver disease portfolio's, building an industry leading pipeline in liver. In all disease areas assets are managed from early development to late stage commercialization, with regular portfolio enrichments through in licensing and acquisitions.

REGISTRATION FORM

PACKAGE NAME:

PROMO CODE

①

Name:

Position:

E-mail:

②

Name:

Position:

E-mail:

③

Name:

Position:

E-mail:

Company:

Address:

City: Postcode:

Phone: VAT No:

Date:

Signature:

This booking is invalid without a signature.

▶ If you are working outside of Europe or you would like to register 6 or more delegates, please contact our Project Director

Contact Details

▶ **Diogo Lino Ribeiro**
Project Director, Europe | Porto Office
EM: diogo.ribeiro@epmgroup.org
PH: +351 915 239 640

Use the promo code "BIOTECH17" and get these discounts:

- € 700 book before 15th of January
- € 400 book before 15th of February
- € 150 book before 15th of March

Conference Package – € 1,895

- 2 days Summit + Master Classes + Interactive Sessions
- Discussion with Industry Experts
- Business Lunches
- Gala Dinner

Standard Package – € 1,995

- Douro River Cruise
- Pre-summit Dinner
- 2 day Summit + Master Classes + Interactive Sessions
- Discussion with Industry Experts
- Business Lunches
- Gala Dinner

Exhibition Booth – € 3,495

- 3 sq.m. Exhibition Space
- 2 Tickets Standard Package

VIP Package – € 3,550

- 3 nights in a 5* Hotel for 1 or 2 persons
- Gala Dinner and Porto Card for Accompanying Person
- Free transport during the 3 days summit
- Airport Pick-up/Drop-off
- Douro River Cruise
- Pre-summit Dinner
- Fast-Registration
- VIP conference seats
- VIP table at the pre-summit dinner/gala dinner
- 2 day Summit + Master Classes + Interactive Sessions
- Discussion with Industry Experts
- Business Lunches
- Gala Dinner

Keynote Sponsorship – € 4,999

- Speaking slot [40 min]
- 2 Ticket standard Package
- Acknowledgement in the opening address
- Logo on conference web-site (with link to company web-site) and on conference proceedings
- 25% discount on extra ticket
- Branding at post-event communication activities

Speaker Sponsorship – € 5,999

- Speaking slot [40 min]
- Company banner displayed at speaker's table
- 3 tickets standard package
- Logo on conference web-site (with link to company web-site) and on brochure
- 50% discount on extra ticket
- Branding at the event (rolling power-point presentation during breaks) and at post-event communication activities
- Acknowledgement in opening address
- Branding at post-event communication activities

Check other Sponsorship options on the next page

Terms and Conditions

By sending this form, I confirm that I have read and accepted the terms and conditions detailed below.

Confirmation
We will confirm your participation after receiving the signed registration form the delegate will receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 weeks before the start of the conference.

Cancellations
Cancellations made one month prior to the start of the conference will be refunded less 50% administration charge. Refunds will be made after the conference. Cancellations made within one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.

Force Majeure
While every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, part refunds or alternative offers shall be made (including, but not limited to any force majeure occurence) and provided that the event is not postponed to a later date nor is it merged with another event, the client shall receive a credit note for the amount that the client has paid to such permanently canceled event. No refunds, part refunds or alternative offers shall be made.

Copyright

All Prices displayed include VAT @ 23% The VAT amount will be displayed after the payment process and shown on your invoice.

SPONSORSHIP PACKAGES

Exhibition Sponsorship – € 6,999

- 6 m2 Exhibition Space
- 3-Tickets standard Package
- Logo on conference Website (with link to company website)
- Logo on conference brochure

Coffee Break Sponsorship [30 min] – €4,000

- 1-ticket standard package
- Company banner displayed at the coffee area
- Logo on conference program and other marketing channels
- 25% discount on extra delegate ticket
- Branding at the event (rolling logo during breaks)
- Branding at post-event communication activities

Reception Sponsorship – €4,999

- 1-ticket standard package
- Company banner displayed at the event: Reception
- Logo on conference brochure other marketing channels
- Logo on conference web-site (with link to company web-site)
- 25% discount on extra delegate ticket
- Branding at the event (rolling logo during breaks)
- Branding at post-event communication activities

Bronze – €6,999

- Banner display in the exhibit space
- 2-Tickets Standard Package
- Logo on conference program and other marketing channels (out-reach 15,000 relevant impressions)
- Logo on conference web-site (with link to company web-site) and on conference proceedings
- 1/4 page ad in final program
- 15% discount on extra delegate ticket
- Branding at the event (rolling power-point presentation during breaks) and at post-event communication activities

Cruise Sponsorship – 7,999€

- 2-ticket standard package
- Company banner and other materials displayed and distributed during the Douro River Cuise
- Logo on conference brochure other marketing channels
- Logo on conference web-site (with link to company web-site)
- 25% discount on extra delegate ticket
- Branding at the event (rolling logo during breaks)
- Branding at post-event communication activities

Silver – €8,999

- Opportunity to give a speech at the beginning of conference (10 minutes)
- Acknowledgement in the opening address
- 3-Tickets Standard Package
- Logo on conference program and other marketing channels (outreach 30,000 relevant impressions)
- Logo on conference web-site (with link to company web-site)
- Logo on conference proceedings
- 1/4 page ad in final program
- 25% discount on extra delegate ticket
- Branding at the event (rolling power-point presentation during breaks) and at post-event communication activities

Gold – €9,999

- Opportunity to give a speech at the beginning of conference (20 minutes)
- Acknowledgement in the opening address
- 6 m2 exhibition space
- 1 Ticket VIP package or 3 tickets standard package
- Logo on conference program, conference proceedings and other marketing channels (outreach 50,000 relevant impressions)
- Logo on conference web-site (with link to company web-site) and 1/2 page ad in final program
- 30% discount on extra delegate ticket
- Flexible Branding at the event (choose in which occasion you would like to make your branding - leaflets etc.) sponsor provides materials
- List of attendees

Platinum – €11,999

- Opportunity to give a speech at the beginning of conference (40 minutes)
- Opportunity to host a sponsored designed social event (cost taken by sponsor)
- Acknowledgement in the opening address
- Organizing an own seminar/workshop within the conference program
- 8 m2 exhibition space
- 2 Tickets VIP package or 4 tickets standard package
- Logo on conference program, web-site (with link to company web-site), conference proceedings and other marketing channels
- Full page ad in final program
- 50% of discount on extra delegate ticket
- Flexible Branding at the event (choose in which occasion you would like to make your branding - leaflets etc.) sponsor provides materials
- List of attendees

All Prices displayed include VAT @ 23% The VAT amount will be displayed after the payment process and shown on your invoice.